Healthcare - Biotechnology - NASDAQ - CA
$ 1.7
-6.08 %
$ 90.6 M
Market Cap
-1.68
P/E
CASH FLOW STATEMENT
-46.4 M
OPERATING CASH FLOW
4.76 M
INVESTING CASH FLOW
47.8 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Milestone Pharmaceuticals Inc.
| Net Income | -59.7 M |
| Depreciation & Amortization | 92 K |
| Capital Expenditures | -112 K |
| Stock-Based Compensation | 9.53 M |
| Change in Working Capital | 1.24 M |
| Others | 2.6 M |
| Free Cash Flow | -46.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (59.7) | (58.4) | (42.9) | (50.0) | (55.2) | (23.2) | (8.1) |
| Depreciation & Amortization | 92 K | 89 K | 93 K | 97 K | 38 K | 10 K | 8 K |
| Deferred Income Tax | 0 | 0 | (7.3) | (5.5) | (1.6) | 0 | 0 |
| Stock Based Compensation | 9.5 | 9.0 | 7.3 | 4.9 | 1.2 | 0.6 | 0.2 |
| Other Operating Activities | 2.4 | 44 K | 7.3 | 5.5 | 1.6 | 0.8 | 59 K |
| Change in Working Capital | 1.2 | (3.3) | 2.3 | (5.8) | 2.8 | 1.5 | (0.2) |
| Cash From Operations | (46.4) | (52.5) | (33.2) | (50.7) | (51.2) | (21.0) | (8.1) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (0.1) | (0.3) | 0 | 0 | (0.4) | 5 K | 36 K |
| Other Items | 4.9 | (56.9) | 70.0 | (70.0) | 29 K | 16.0 | (16.0) |
| Cash From Investing Activities | 4.8 | (57.1) | 70.0 | (70.0) | (0.4) | 16.0 | (16.0) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 50.0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.2) | 0.5 | 5.1 | 48.3 | 44 K | 80.1 | 30.7 |
| Cash From Financing Activities | 47.8 | 3.1 | 5.1 | 73.2 | 85.4 | 80.1 | 30.7 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 6.1 | (106.5) | 41.8 | (47.5) | 33.9 | 75.1 | 6.6 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (46.5) | (52.7) | (33.2) | (50.7) | (51.6) | (21.1) | (8.1) |